granuloma faciale
Conditions
Interventions
The adalimumab group:Not applicable
Sponsors
The First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) age greater than or equal to 18 years; 2) patients diagnosed with facial granuloma according to the accepted clinical and histopathological criteria; 3) If patients were receiving systemic therapy, this therapy had to be discontinued and, after a 4-week washout period, patients were kept off other medications during the study; 4) If the patient was receiving topical therapy, this therapy had to be discontinued, and after a 2-week washout period, the patient was kept off other medications during the study; 5) Women of childbearing potential must consent to use contraception during pregnancy 6) patients with written informed consent;
Exclusion criteria
Exclusion criteria: 1) pregnant and lactating women; 2) pregnant or lactating women of childbearing potential who are unable or unwilling to use contraception; 3) patients with acute or chronic infection, or with a history of active tuberculosis or hepatitis; 4) subjects with malignant tumors; 5) taking other immunosuppressive drugs at the same time, including but not limited to cyclosporine, tacrolimus and other drugs; 6) patients with severe heart, liver, kidney and other organ and systemic diseases; 7) Use of the trial drug was deemed inappropriate by other investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving complete clinical remission (CR).; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with a partial clinical response (PR);Changes of lesion surface characteristics by dermoscopy; | — |
Countries
China
Contacts
Public ContactZheng Song
The First Affiliated Hospital of China Medical University
Outcome results
None listed